Chemours (NYSE:CC – Get Rating) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Saturday.
CC has been the subject of a number of other research reports. Credit Suisse Group dropped their price objective on Chemours from $27.00 to $25.00 in a report on Friday, April 28th. Royal Bank of Canada boosted their target price on Chemours from $35.00 to $36.00 in a research note on Monday, May 1st. Citigroup boosted their target price on Chemours from $33.00 to $35.00 and gave the company a “neutral” rating in a research note on Monday, February 13th. UBS Group raised Chemours from a “neutral” rating to a “buy” rating and boosted their target price for the company from $31.00 to $43.00 in a research note on Tuesday, January 24th. Finally, The Goldman Sachs Group boosted their target price on Chemours from $34.00 to $38.00 and gave the company a “neutral” rating in a research note on Tuesday, February 14th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $36.11.
Chemours Price Performance
Shares of CC stock opened at $29.68 on Friday. The stock has a 50 day moving average of $29.17 and a two-hundred day moving average of $31.44. The company has a current ratio of 1.84, a quick ratio of 0.98 and a debt-to-equity ratio of 2.93. Chemours has a 12 month low of $23.58 and a 12 month high of $44.95. The company has a market capitalization of $4.43 billion, a P/E ratio of 9.57, a P/E/G ratio of 0.91 and a beta of 1.87.
Insider Transactions at Chemours
In other news, insider Alisha Bellezza sold 27,716 shares of the business’s stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $35.47, for a total transaction of $983,086.52. Following the sale, the insider now directly owns 43,931 shares in the company, valued at $1,558,232.57. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 1.63% of the company’s stock.
Hedge Funds Weigh In On Chemours
A number of institutional investors have recently modified their holdings of CC. Ameritas Advisory Services LLC bought a new stake in Chemours during the first quarter worth $29,000. Lindbrook Capital LLC grew its holdings in Chemours by 117.3% during the fourth quarter. Lindbrook Capital LLC now owns 969 shares of the specialty chemicals company’s stock worth $30,000 after buying an additional 523 shares in the last quarter. Operose Advisors LLC bought a new stake in Chemours during the first quarter worth $33,000. Tanglewood Legacy Advisors LLC bought a new stake in Chemours during the fourth quarter worth $41,000. Finally, GPS Wealth Strategies Group LLC bought a new stake in Chemours during the first quarter worth $47,000. 71.89% of the stock is owned by institutional investors and hedge funds.
Chemours Company Profile
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
- Get a free copy of the StockNews.com research report on Chemours (CC)
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
- Foot Locker And The Ebbing Tide Of Discretionary Spending
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.